Stocktoria
Viking Therapeutics, Inc. VKTX
Viking Therapeutics, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| R&D expense | $345.0M | $101.6M | $63.8M | $54.2M | $45.0M | $31.9M | $23.6M | $19.0M | $13.7M | $9.0M |
| Operating income | -$393.3M | -$150.9M | -$100.8M | -$70.4M | -$55.7M | -$42.7M | -$32.7M | -$26.2M | -$19.1M | -$13.8M |
| Income tax | $1,000 | $1,000 | $1,000 | $1,000 | $2,000 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$359.6M | -$110.0M | -$85.9M | -$68.9M | -$55.0M | -$39.5M | -$25.8M | -$22.1M | -$20.6M | -$14.7M |
| EPS (diluted) | $-3.19 | $-1.01 | $-0.91 | $-0.90 | $-0.71 | — | — | — | — | — |
| Operating cash flow | -$278.7M | -$87.8M | -$73.4M | -$48.4M | -$47.6M | -$21.8M | -$24.8M | -$18.8M | -$14.8M | -$11.1M |
| Cash & equivalents | $165.8M | $26.7M | $55.5M | $36.6M | $26.4M | $29.1M | $8.4M | $24.8M | $9.0M | $3.1M |
| Total assets | $715.7M | $908.3M | $368.5M | $168.5M | $210.7M | $256.5M | $284.3M | $302.3M | $22.1M | $14.5M |
| Total liabilities | $76.7M | $28.0M | $20.1M | $23.2M | $8.8M | $12.2M | $7.1M | $4.6M | $8.7M | $6.5M |
| Shareholders' equity | $639.1M | $880.3M | $348.4M | $145.3M | $201.9M | $244.3M | $277.1M | $297.8M | $13.5M | $8.0M |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.